Ioflupane I123 Injection (DaTscan™) SPECT Brain Imaging in Patients with Movement Disorders and/or Dementia: Preliminary Report

Keywords
Diagnostic accuracy; Sensitivity; Specificity; SPECT; Ioflupane I123 Injection; DaTscan; DaTscan; Parkinson’s disease; Movement disorders; Dementia

Abbreviations
AD: Alzheimer’s Disease; DLB: Dementia with Lewy Bodies; ET: Essential Tremor; MSA: Multiple System Atrophy; PD: Parkinson’s Disease; PS: Parkinsonian Syndrome; PSP: Progressive Supranuclear Palsy; SPECT: Single-Photon Emission Computed Tomography; SWEDDs: Scans Without Evidence of Dopaminergic Deficit

Introduction
Early and accurate diagnosis of movement disorders and dementia is critically important to ensure patients receive appropriate treatment. Ioflupane I123 injection (ioflupane (123I) or (123I) FP-CIT or DaTscan™ or DaTscan™) is approved in Europe and the US for diagnostic use only, for detecting loss of functional dopaminergic neuron terminals in the striatum in patients with clinically uncertain parkinsonian syndromes (PS), including those at an early stage, to help differentiate essential tremor (ET) from PS related to Parkinson’s disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). Ioflupane (123I) is unable to discriminate between PD, MSA, and PSP. In Europe, ioflupane (123I) is also approving to help differentiate probable dementia with Lewy bodies (DLB) from Alzheimer’s disease (AD). Ioflupane (123I) is not able to discriminate between dementia with Lewy bodies and Parkinson’s disease dementia (Table 1).

The clinical differentiation of conditions with presynaptic dopaminergic deficit from those without such deficit is sometimes difficult. Diagnostic error, such as “over-calling” of PD, has been seen in autopsy studies, in which Lewy body degeneration was absent in vascular Parkinsonism [1]. Several studies evaluating various medication protocols in patients diagnosed clinically as early PD had, in fact, normal imaging results in 4-14% of the cases [2-4]. In subjects with clinically uncertain PS, diagnoses were changed from PS to non-PS in 14.7% of subjects, as a result of normal imaging results, and changes to baseline diagnostic category are more likely to occur after ioflupane (123I) imaging is performed than if it is not (45% vs. 9%, respectively; P<0.001).
Ioflupane I123 Injection (DaTscan™) SPECT Brain Imaging in Patients with Movement Disorders and/or Dementia: Preliminary Report

Table 1: Ioflupane I123 Injection Approved Indications.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ioflupane (Ioflupane I123 Injection) is a radiopharmaceutical indicated for striatal dopamine transporter visualization using Single Photon Emission Computed Tomography (SPECT) brain imaging to assist in the evaluation of adult patients with suspected Parkinsonian Syndromes (PS). In these patients, DaTscan™ may be used to help differentiate essential tremor from tremor due to PS (idiopathic Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy). DaTscan™ is an adjunct to other diagnostic evaluations.</td>
<td>This medicinal product is for diagnostic use only. DaTscan™ is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum. In adult patients with clinically uncertain Parkinsonian Syndromes, for example those with early symptoms, in order to help differentiate Essential Tremor from Parkinsonian Syndromes related to idopathic Parkinson’s Disease, Multiple System Atrophy and Progressive Supranuclear Palsy. DaTscan™ is unable to discriminate between Parkinson’s Disease, Multiple System Atrophy and Progressive Supranuclear Palsy. In adult patients, to help differentiate probable dementia with Lewy bodies from Alzheimer’s disease. DaTscan™ is unable to discriminate between dementia with Lewy bodies and Parkinson’s disease dementia.</td>
</tr>
</tbody>
</table>

Despite obtaining high sensitivity and specificity overall, mismatches between the clinical diagnosis and dopamine transporter imaging results did occur. There are several possible explanations for why mismatches occur. One explanation is that during image acquisition, the level of dopaminergic transporter deficiency may be insufficient to show up on Ioflupane (123I) images. This is highly unlikely in PS, because dopamine cell loss has been shown to be greater than 50% at clinical presentation [14]. It is also unlikely in DLB, because abnormal scans have been observed in patients in which Parkinsonism was minimal [10]. Mismatches are more likely attributable to incomplete clinical features than imaging deficiencies. In PS, only one of three cardinal signs at presentation, two signs without bradykinesia, doubtful bradykinesia or postural rather than rest tremor might confound the diagnosis [5]. Advanced PD cases with three cardinal signs including tremor syndrome predominance and responsive to L-Dopa typically diagnosed well without scan. Patients presenting with adult-onset dystonic tremor may mimic parkinsonian tremor and bradykinesia and have scans without evidence of dopaminergic deficit (SWEDDs) [15]. Drug-induced Parkinsonism can mimic PD, including asymmetry of clinical features, and drug withdrawal is not always feasible to confirm the etiology [16]. In DLB, clinical diagnostic confidence is low in cases of possible disease, with only approximately one quarter of them being confirmed pathologically as DLB [17]. When Ioflupane (123I) imaging was performed in subjects with possible DLB, 38% showed abnormal results [10], supporting the helpfulness of a specificity value of 90.1%.

This pooled analysis will demonstrate that the visual assessment of Ioflupane (123I) images provided high levels of sensitivity and specificity in detecting the presence or absence of a striatal dopaminergic deficit. In cases of diagnostic uncertainty, it is appropriate to use Ioflupane (123I) imaging when the diagnostic considerations include disorders that exhibit striatal dopaminergic deficit versus those that do not. Ioflupane (123I) brain imaging has the potential to improve diagnostic accuracy in patients with signs and symptoms of a movement disorder and/or dementia.

Acknowledgements

This pooled analysis was funded by GE Healthcare.

Conflict of Interest

- IDG is an employee of GE Healthcare and does not hold any stocks or shares, or have other financial competing interests.
- KT has received personal fees for performing DaTscan SPECT image reads during clinical trials and honoraria for lectures from GE Healthcare.
- ET has received personal fees for research, lectures and consultancy from Novartis, TEVA, Boehringer Ingelheim, UCB, Solvay, and Lundbeck; grants from the Spanish government.
References


